Biotricity has introduced a direct-to-consumer heart monitor, Bioheart, which offers continuous heart monitoring for people diagnosed with or at risk for cardiovascular disease.

The new heart monitor leverages advanced heart technology, analytics and continuous rhythm monitoring to deliver feedback required to understand heart health.

The continuous monitoring and long-term data collection approach would help users analyse previous heart data, months after the initial recording, said the company.

Bioheart is compatible with both iOS and Android devices and uses Bluetooth 4.2.0 to pair with your smartphone to offer real-time data on the Bioheart app.

It offers summaries on metrics such as heart rate during rest and activity, live heart rhythm, heart rate variability, and more for advanced health tracking and performance optimisation.

Biotricity founder and CEO Waqaas Al-Siddiq said: “Launching Bioheart and expanding into this new market is an important step for Biotricity and our ultimate goal of building a complete cardiac ecosystem to service individuals throughout their heart health journey.

“Bioheart combines unparalleled accuracy in a heart monitoring device with continuous data, advanced heart health insights, and powerful features tailored to individuals at risk for heart disease or who want precise data for performance tracking, optimisation and preventative cardiac wellness.”

According to the company, heart condition signs are typically intermittent, where most heart monitoring devices only capture short periods of heart activity.

Most of the devices fail to provide heart data or tools required to support preventative care and lifestyle improvements.

Biotricity said that its Bioheart comes with a removable and washable fabric strap that is breathable and waterproof, and a rechargeable battery.

The device is said to open a new market and revenue stream for the company, while expanding its total market by $1.2bn in the heart rate monitoring market.

Waqaas added: “Bioheart furthers Biotricity’s mission of developing revolutionary healthcare solutions that help engage and empower individuals to take control of their health, starting with the deadliest chronic disease and one of healthcare’s largest cost drivers: cardiac disease.

“As a direct manufacturer, we’re thrilled to have been able to accelerate our market delivery to the general market in less than a year, ahead of schedule and in time for the busy holiday gifting season.”